Literature DB >> 26135874

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.

Norio Akuta1, Fumitaka Suzuki2, Masahiro Kobayashi2, Hitomi Sezaki2, Yusuke Kawamura2, Tetsuya Hosaka2, Mariko Kobayashi3, Satoshi Saitoh2, Yoshiyuki Suzuki2, Yasuji Arase2, Kenji Ikeda2, Hiromitsu Kumada2.   

Abstract

The impact of the HCV genotype 1b core amino acid (aa) 70 mutant on the cumulative rate of hepatocellular carcinoma following eradication of HCV RNA by antiviral therapy was investigated with the Q-Invader assay. Multivariate analysis based on 649 patients indicated that a core aa70 Q-Invader mutant level ≥20% is a predictor of hepatocellular carcinoma.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26135874      PMCID： PMC4540910          DOI： 10.1128/JCM.01457-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

Authors:  Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

2.  Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Authors:  Hajime Tokita; Hideo Fukui; Akihisa Tanaka; Hiroshi Kamitsukasa; Michiyasu Yagura; Hideharu Harada; Hiroaki Okamoto
Journal:  J Gastroenterol Hepatol       Date:  2005-05       Impact factor: 4.029

3.  Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Authors:  S Kobayashi; T Takeda; M Enomoto; A Tamori; N Kawada; D Habu; H Sakaguchi; T Kuroda; K Kioka; S R Kim; T Kanno; T Ueda; M Hirano; S Fujimoto; H Jomura; S Nishiguchi; S Seki
Journal:  Liver Int       Date:  2007-03       Impact factor: 5.828

4.  Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.

Authors:  Mariko Kobayashi; Norio Akuta; Fumitaka Suzuki; Tetsuya Hosaka; Hitomi Sezaki; Masahiro Kobayashi; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Sachiyo Watahiki; Rie Mineta; Satomi Iwasaki; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2010-01       Impact factor: 2.327

5.  Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients.

Authors:  Kenji Ikeda; Masahiro Kobayashi; Satoshi Saitoh; Takashi Someya; Tetsuya Hosaka; Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Oncology       Date:  2003       Impact factor: 2.935

6.  Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Authors:  Miharu Hirakawa; Kenji Ikeda; Yasuji Arase; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

7.  Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.

Authors:  Sarah L Fishman; Stephanie H Factor; Cinzia Balestrieri; Xiaofeng Fan; Adrian M Dibisceglie; Suresh M Desai; Gary Benson; Andrea D Branch
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

8.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

9.  Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Sachiyo Watahiki; Junko Sato; Marie Matsuda; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Intervirology       Date:  2005       Impact factor: 1.763

10.  Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Authors:  Hiromitsu Kumada; Yoshiyuki Suzuki; Kenji Ikeda; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Akio Ido; Kazuhide Yamamoto; Koichi Takaguchi; Namiki Izumi; Kazuhiko Koike; Tetsuo Takehara; Norifumi Kawada; Michio Sata; Hidetaka Miyagoshi; Timothy Eley; Fiona McPhee; Andrew Damokosh; Hiroki Ishikawa; Eric Hughes
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425
View more
  7 in total

Review 1.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

2.  Subgenotyping and genetic variability of hepatitis C virus in Palestine.

Authors:  Sahar Rayan Da'as; Maysa Azzeh
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240

Review 3.  Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

Authors:  Simonetta Bandiera; C Billie Bian; Yujin Hoshida; Thomas F Baumert; Mirjam B Zeisel
Journal:  Curr Opin Virol       Date:  2016-10-11       Impact factor: 7.121

4.  Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients.

Authors:  Ahmed El-Shamy; Matthew Pendleton; Francis J Eng; Erin H Doyle; Ali Bashir; Andrea D Branch
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

5.  Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context.

Authors:  V S Kichatova; K K Kyuregyan; N V Soboleva; A A Karlsen; O V Isaeva; M G Isaguliants; M I Mikhailov
Journal:  J Immunol Res       Date:  2018-02-07       Impact factor: 4.818

6.  Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Authors:  Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Masahiro Kobayashi; Shunichiro Fujiyama; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

Review 7.  Viral hepatitis and liver cancer.

Authors:  Marc Ringelhan; Jane A McKeating; Ulrike Protzer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.